Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000041.xml
Neuropediatrics 1994; 25(1): 39-41
DOI: 10.1055/s-2008-1071580
DOI: 10.1055/s-2008-1071580
Short communication
© Georg Thieme Verlag KG Stuttgart · New York
Etoposide Treatment in Recurrent Medulloblastoma
Further Information
Publication History
Publication Date:
15 May 2008 (online)
Abstract
Five consecutive patients with recurrent medulloblastoma received etoposide 120 mg/m2 for 5 to 7 days at 2 to 4 week intervals. Three patients with neuroaxis dissemination received additional intrathecal chemotherapy with methotrexate, cytosin arabinoside and prednisone. Toxicity consisted of alopecia and mild neutropenia. Complete response was registered in two patients, partial response in one. Median survival was 19 months with the 3 responders living 6, 30 and 60 + months. Etoposide seems to be an active agent in medulloblastoma.
Key words
Etoposide - Recurrent medulloblastoma